SCHEMBL7248796

SCHEMBL7248796

CC(C)CCc1cc[c]cc1CN1CCCCC1C

nearest known ligand 0.43

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.42
KMT2A Q03164 6/20 0.42
KDM4E B2RXH2 3/20 0.42
MAPT P10636 2/20 0.42
NPSR1 Q6W5P4 2/20 0.42
MEN1 O00255 3/20 0.38
HRH3 Q9Y5N1 4/20 0.37
CRHBP P24387 1/20 0.37
CRHR2 Q13324 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
GAA P10253 1/20 0.36
HPGD P15428 1/20 0.36
TSHR P16473 1/20 0.36
HSD17B10 Q99714 1/20 0.36
POLB P06746 1/20 0.35
LMNA P02545 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5109651 0.79 ALDH1A1 (0.36) ALDH1A1KMT2AKDM4EMAPTMEN1
SCHEMBL7248795 0.78 KMT2A (0.44) ALDH1A1KMT2AKDM4EMAPTNPSR1
SCHEMBL7244714 0.74 PABPC1 (0.38) ALDH1A1KMT2AKDM4ENPSR1MEN1
SCHEMBL22121688 0.74 HRH3 (0.42) ALDH1A1KMT2AKDM4EMAPTNPSR1
SCHEMBL22121690 0.74 HRH3 (0.42) ALDH1A1KMT2AKDM4EMAPTNPSR1
SCHEMBL22121744 0.74 HRH3 (0.42) ALDH1A1KMT2AKDM4EMAPTNPSR1
SCHEMBL7252847 0.73 PABPC1 (0.40) ALDH1A1KMT2AKDM4EMEN1HRH3
SCHEMBL676980 0.73
SCHEMBL7243660 0.72 PABPC1 (0.35) ALDH1A1KMT2AKDM4EMAPTNPSR1
SCHEMBL5103802 0.72 NPSR1 (0.44) ALDH1A1KMT2AKDM4EMAPTNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6627624-B1 Agonists, antagonists or inverse agonists for GABAa brain receptors or prodrugs of agonists, antagonists or inverse agonists for GABAa brain receptors, and are therefore useful in the diagnosis and treatment of anxiety, Down Syndrome, NEUROGEN CORPORATION 2003-09-30 US disclosed